Analysis Affinity and Kinetics of Monoclonal Antibody (mAb) against Membrane Proteins by KinExA (CAT#: STEM-MB-0065-CJ)

Introduction

Monoclonal antibody (mAb) therapeutics have formed and continue to form the vast majority of biopharmaceutical company pipelines today with a number of remarkable commercial successes. The advent of mAbs as therapeutics has been greatly aided by a process platform approach that has enabled rapid development and manufacturing for this class of drugs. Meanwhile monoclonal antibody is an illustration of a remarkable translational scientific discovery and its bench-to-bedside journey took around a decade to be materialized into the clinical application of its use. However, a balance between the cost of treatment, efficacy and safety need to be considered as the treatment with mAbs can be expensive. Hence, more robust data on their cost effectiveness and long-term safety are warranted.